Femasys Inc. (FEMY)
| Market Cap | 21.54M -32.4% |
| Revenue (ttm) | 2.38M +39.9% |
| Net Income | -11.88M |
| EPS | -0.24 |
| Shares Out | 60.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,103 |
| Open | 0.3800 |
| Previous Close | 0.3806 |
| Day's Range | 0.3566 - 0.3855 |
| 52-Week Range | 0.3067 - 1.1100 |
| Beta | -2.25 |
| Analysts | Strong Buy |
| Price Target | 5.33 (+1,394.67%) |
| Earnings Date | May 8, 2026 |
About FEMY
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It ... [Read more]
Financial Performance
In 2025, Femasys's revenue was $2.29 million, an increase of 40.77% compared to the previous year's $1.63 million. Losses were -$18.63 million, -1.00% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for FEMY stock is "Strong Buy." The 12-month stock price target is $5.33, which is an increase of 1,394.67% from the latest price.
News
Femasys announces CE Mark approval for FemHSG Catheter
Femasys (FEMY) announced CE Mark approval for its FemHSG Catheter, further expanding the company’s portfolio in Europe through commercial partners.
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertili...
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femas...
Femasys drives growth with Israeli market entry for fertility portfolio
Femasys (FEMY) announced a strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel. This collaboration marks an important step in the Company’s glo...
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execu...
Femasys management to meet virtually with Lake Street
Virtual Meeting to be held on March 26 hosted by Lake Street.
Femasys appoints Kenneth Eichenbaum to its Board of Directors
Femasys (FEMY) announced the appointment of Kenneth D. Eichenbaum, to its Board of Directors. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Bea...
Femasys advances FemBloc to U.S. approval with initiation of trial enrollment
Femasys (FEMY) announced the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration, FDA, Investigational De...
Femasys initiated with a Buy at Lake Street
Lake Street analyst Ben Haynor initiated coverage of Femasys (FEMY) with a Buy rating and $1.50 price target FemBloc is the first and only non-surgical alternative that can be performed…
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to w...
Femasys FemBloc achieved certification under MDSAP
Femasys (FEMY) announced that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program, MDSAP. The MDSAP certification positions the Company ...
Femasys receives AMA CPT Editorial Panel approval for new CPT code
Femasys (FEMY) announced that it has received notice from the American Medical Association, AMA, CPT Editorial Panel approving a new Category III Current Procedural Terminology, CPT, code covering the...
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedica...
Femasys enters distribution partnership with OR Consulting
Femasys (FEMY) announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent ...
Femasys granted 180-day extension by Nasdaq to regain compliance
Femasys (FEMY) announced that on January 13, 2026, it received notification from The Nasdaq Stock Market that Nasdaq approved the Company’s request for an additional 180-calendar day extension to rega...
Femasys announces partnership with Refuah Health Center
Femasys (FEMY) announced a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. “This partnership is an important step forward in expanding…
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population Partnership enables broader adoption of FemaSeed through a trus...
Femasys files to sell 68.42M shares of common stock for holders
16:38 EST Femasys (FEMY) files to sell 68.42M shares of common stock for holders
Femasys secures U.S. FDA clearance for FemVue Controlled device
Femasys (FEMY) announced it has received 510(k) clearance from the United States Food and Drug Administration, FDA, for its FemVue Controlled device, an innovative diagnostic solution designed for con...
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) ...
PharmaCyte sells Femasys stake, sees cash position rising to $20M
PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to inc...
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further val...
Femasys initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen initiated coverage of Femasys (FEMY) with a Buy rating and $6.50 price target Femasys is a development stage medical technology company focusing on two lead women…
Femasys advances global growth with second partner order for FemBloc in Europe
Femasys (FEMY) announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its part...